Korea’s reimbursement authorities delivered two high-impact decisions that reset competitive positions in neurology and oncology. AstraZeneca’s Ultomiris secured insurance coverage for a narrow but clinically complex segment of generalized myasthenia gravis, while GSK’s Jemperli achieved first-line reimbursement for dMMR/MSI-H endometrial cancer, effectively establishing the PD-1 inhibitor as the standard option in its biomarker-defined segment. Although the two decisions operate in unrelated therapeutic spaces, both illustrate Korea’s increasingly data-driven reimbursement logic, targeted patient selection, strong pivotal-trial evidence, and willingness to recognize durability as a reimbursement-worthy determinant of value.
What You Need To Know
- Korea granted reimbursement for Ultomiris in a narrowly defined, therapy-refractory GMG population, anchored in CHAMPION-MG efficacy and durability data.
- Strict coverage criteria limit the eligible GMG population despite strong long-term outcomes in neuromuscular function.
- Jemperli secured first-line reimbursement for dMMR/MSI-H endometrial cancer, becoming the only reimbursed immunotherapy across both first- and second-line settings in Korea.
- RUBY trial results, with a 16.4-month OS gain and 72 percent mortality-risk reduction at 24 months, were central to Korea’s reimbursement determination.
AstraZeneca Korea’s Ultomiris (ravulizumab) now enters the Korean health system for adult patients with anti-AChR-positive generalized myasthenia gravis, a population characterized by fluctuating neuromuscular weakness and unpredictable crises. The reimbursement criteria, outlined in the national coverage notice, define a narrowly filtered cohort: MGFA class II–IV disease, MG-ADL score ≥6, a prior myasthenic crisis requiring plasmapheresis or IVIg, and demonstrated refractoriness or intolerance to corticosteroids plus at least two immunosuppressants. Patients in active crisis and those within 12 months post-thymectomy remain excluded.
The regulatory body’s tight gating reflects a longstanding tension, GMG’s burden is significant and chronic, yet existing immunosuppressive regimens carry substantial toxicity and incomplete control. Korea’s decision therefore draws heavily on data from the 26-week phase 3 CHAMPION-MG trial, which showed that Ultomiris cut MG-ADL scores by 3.1 points versus 1.4 for placebo (P<0.001). The antibody also more than doubled the proportion of ≥5-point responders on the QMG muscle-strength scale (30.0 percent vs. 11.3 percent; P=0.005). The long-term extension added further weight, a 4-point MG-ADL improvement at 164 weeks and nearly 42 percent of responders reaching minimal symptom manifestation.
Despite clinical robustness, coverage remains highly restrictive. Neurologists quoted in Korea emphasize that only a small fraction of real-world GMG patients can meet the current eligibility framework, urging further relaxation to align reimbursement with disease volatility and day-to-day functional constraints. AstraZeneca Korea, speaking on the decision, framed this coverage as a foundational step toward stabilizing a patient population that has historically cycled unpredictably between partial control and crisis.
If neuromuscular disease gained a selective new option, the oncology landscape experienced a far more expansive shift. GSK’s Jemperli (dostarlimab) secured reimbursement for first-line combination therapy with carboplatin and paclitaxel in newly diagnosed advanced or recurrent dMMR/MSI-H endometrial cancer, marking the first immunotherapy reimbursed in the indication. It is now the only reimbursed therapy occupying both first- and second-line settings in its biomarker-defined subgroup.
Jemperli’s ascent to standard position is tied almost entirely to the phase 3 RUBY trial, which enrolled 494 patients across high-risk histology’s. The dMMR/MSI-H subgroup delivered the most pronounced benefit, median overall survival reached 44.6 months versus 28.2 for control, translating to a 72 percent reduction in risk of death at the 24-month analysis. Progression-free survival at 24 months was 61.4 percent for the combination versus 15.7 percent for placebo. At 36 months, overall survival remained sharply separated (74 percent vs. 46 percent).
Korea’s decision arrives after incremental regulatory expansions in 2022, 2023, 2024, and early 2025, culminating in a reimbursement stance that recognizes durable survival as a threshold determinant of economic value. Experts speaking at GSK Korea’s press roundtable underscored the significance, platinum-based chemotherapy has delivered median survival of less than three years for decades. The RUBY data reset expectations not only for biomarker-positive populations but also for pMMR patients, where benefits are more modest but directionally consistent.
GSK Korea is positioning Jemperli as a backbone immunotherapy in first-line endometrial cancer and is already evaluating combination strategies, including antibody-drug conjugates and targeted agents. The company publicly framed the reimbursement expansion as both a patient-access milestone and a platform for next-generation regimens.